Daily CBD use at typical consumer doses led to significant liver enzyme elevations in healthy adults. About 6% of CBD users had liver enzymes over three times the normal upper limit. CBD use is common ...
An international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one ...
Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...
CHINO, Calif., March 12, 2025 /PRNewswire/ -- Specialty Enzymes & Probiotics is proud to announce that its powerful research-backed sports nutrition ingredient, DigeSEB Sport™, has earned Non-GMO ...
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions ...
Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free ...
Daily use of cannabidiol (CBD) at doses commonly reported by consumers was associated with potentially dangerous increases in liver enzymes, a randomized clinical trial found. Among 201 healthy adult ...
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback